Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine

Hum Gene Ther. 1997 May 20;8(8):985-1001. doi: 10.1089/hum.1997.8.8-985.

Authors

R G Crystal¹, E Hirschowitz, M Lieberman, J Daly, E Kazam, C Henschke, D Yankelevitz, N Kemeny, R Silverstein, A Ohwada, T Russi, A Mastrangeli, A Sanders, J Cooke, B G Harvey

Affiliation

¹ Rockefeller University Hospital, New York, New York 10021, USA.

PMID: 9195221
DOI: 10.1089/hum.1997.8.8-985

No abstract available

Publication types

Clinical Trial
Clinical Trial, Phase I

MeSH terms

Adenoviridae / genetics*
Administration, Oral
Adolescent
Adult
Antimetabolites / therapeutic use*
Colonic Neoplasms / pathology
Cytosine Deaminase
Escherichia coli / enzymology
Escherichia coli / genetics
Female
Flucytosine / therapeutic use*
Genetic Therapy*
Genetic Vectors*
Humans
Liver Neoplasms / secondary
Liver Neoplasms / therapy*
Male
Nucleoside Deaminases / genetics
Prodrugs / therapeutic use*
Virus Replication / genetics

Substances

Antimetabolites
Prodrugs
Flucytosine
Nucleoside Deaminases
Cytosine Deaminase